肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2012年
9期
627-630
,共4页
鼻咽肿瘤%放射疗法%不良反应
鼻嚥腫瘤%放射療法%不良反應
비인종류%방사요법%불량반응
Nasopharyngeal neoplasms%Radiotherapy%Adverse reactions
目的 观察分析鼻咽癌患者放疗后急性期和晚期不良反应情况.方法 对门诊随访的89例鼻咽癌患者进行填表调查,随访的中位时间为3年(2 ～ 23年).结果 发生率较高的急性期不良反应主要有重度口干[78.7％(70例)]、耳部反应[66.3％(59例)]、鼻腔黏膜反应[64.0％(57例)]；晚期反应有79.8％(71例)患者出现放射性中耳炎表现,其中53.9％(48例)患者出现听力下降,42.7％(38例)出现鼻腔症状,11.2％(10例)仍存在重度口干,66.3％(59例)患者发生2度及以上的龋齿.结论 在鼻咽癌患者放疗后晚期不良反应中,放射性中耳炎和龋齿的发生率较高,同步化疗可能增加或加重急性期放疗不良反应,但并未对晚期不良反应的发生造成影响.
目的 觀察分析鼻嚥癌患者放療後急性期和晚期不良反應情況.方法 對門診隨訪的89例鼻嚥癌患者進行填錶調查,隨訪的中位時間為3年(2 ～ 23年).結果 髮生率較高的急性期不良反應主要有重度口榦[78.7％(70例)]、耳部反應[66.3％(59例)]、鼻腔黏膜反應[64.0％(57例)]；晚期反應有79.8％(71例)患者齣現放射性中耳炎錶現,其中53.9％(48例)患者齣現聽力下降,42.7％(38例)齣現鼻腔癥狀,11.2％(10例)仍存在重度口榦,66.3％(59例)患者髮生2度及以上的齲齒.結論 在鼻嚥癌患者放療後晚期不良反應中,放射性中耳炎和齲齒的髮生率較高,同步化療可能增加或加重急性期放療不良反應,但併未對晚期不良反應的髮生造成影響.
목적 관찰분석비인암환자방료후급성기화만기불량반응정황.방법 대문진수방적89례비인암환자진행전표조사,수방적중위시간위3년(2 ～ 23년).결과 발생솔교고적급성기불량반응주요유중도구간[78.7％(70례)]、이부반응[66.3％(59례)]、비강점막반응[64.0％(57례)]；만기반응유79.8％(71례)환자출현방사성중이염표현,기중53.9％(48례)환자출현은력하강,42.7％(38례)출현비강증상,11.2％(10례)잉존재중도구간,66.3％(59례)환자발생2도급이상적우치.결론 재비인암환자방료후만기불량반응중,방사성중이염화우치적발생솔교고,동보화료가능증가혹가중급성기방료불량반응,단병미대만기불량반응적발생조성영향.
Objective To observe the adverse reactions of acute stage and late stage in nasopharyngeal carcinoma patients after radiotherapy.Methods 89 patients were investigated in the outpatient department by form.The median follow-up time was 3 years (2-23 years).Results In the acute stage,the ratios of serious xerostomia [78.7 ％(70/89)],the ear reaction [66.3 ％ (59/89)] and nose impairment [64.0 ％ (57/89)] were very high.In the late stage 79.8 ％ (71/89) patients developed radioactive tympanitis,in which 53.9 ％ (48/89) patients induced hearing loss,42.7 ％ (38/89) patients developed dry nose or nasal excessive discharge.The rate of serious xerostomia was 11.2 ％ (10/89),66.3 ％(59/89) patients suffered from superficial and more serious caries.Conclusion The rates of the radioactive tympanitis and caries stayed high in the late stage of nasopharyngeal carcinoma patients after radiotherapy.Concurreut chemoradiotherapy is probable to increase or aggravate the incidence of adverse reactions in the acute stage,but don’t show an effect on the late stage reaction.
